|
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain Clinical research trials and A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain. A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain clinical trial. Human subjects often get the best healthcare possible for their A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
For Condition: HIV Infections,Cancer,Pain
Status: Completed
Sponsor(s): Neurex ,
Synopsis: To determine the safety and efficacy of SNX-111 in controlling severe, chronic pain in cancer and AIDS patients.
Details: Patients are randomized to receive SNX-111 or placebo (AS PER AMENDMENT 1/22/98: with randomization weighted 2:1 in favor of SNX-111) via external pump and an intrathecal catheter (thin tube inserted into the spinal canal). (AS PER AMENDMENT 1/22/98: the dose is increased every 24 hours, in the absence of onset of analgesia or adverse events. After 2-5 days, patients who respond to their medication continue treatment at home for 5-8 days. Patients who do not respond will be switched to the other regimen (i.e., placebo to SNX-111, or SNX-111 to placebo). After 10 days, responding patients are unblinded and asked to enroll in the long-term, open-label extension protocol. Patients remain on a fixed dose at the therapeutic level found in the previous study. The dose may be increased or decreased at the discretion of the investigator. Patients may continue therapy on a long-term basis until the drug is approved.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Rescue analgesia. Patients must have: - Chronic pain related to AIDS or cancer. - Unsatisfactory response to prior opioid therapy. - Life expectancy > 3 months (or 1 month if an infusion pump is in place). Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Signs of sepsis or inadequately treated infection. Patients with the following prior conditions are excluded: History of heart disease, heart failure, or asthma.
Total Enrollment: 100
Location and Contact Information:
Bowman Gray School of Medicine / Wake Forest Univ
Winston Salem, North Carolina, 27157
United States
Methodist Hosp
Memphis, Tennessee, 38104
United States
Pain Diagnosis and Treatment
Glendora, California, 917414240
United States
VA Med Ctr / Oncology Section
Washington D.C., District of Columbia, 20422
United States
Good Samaritan Hosp Ctr
San Jose, California, 95124
United States
Neurosurgical Associates
Terre Haute, Indiana, 47804
United States
Minneapolis Veterans Administration
Minneapolis, Minnesota, 55417
United States
Pain Management
New York City, New York, 10021
United States
Holt Krock Clinic
Fort Smith, Arkansas, 72901
United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Northport Hosp
Northport, Alabama, 35476
United States
Lehigh Valley Hosp
Allentown, Pennsylvania, 18104
United States
Northwest Neuroscience Institute
Seattle, Washington, 98133
United States
Connecticut Pain Care
Danbury, Connecticut, 06810
United States
Univ of Tennessee
Memphis, Tennessee, 38163
United States
Univ of Iowa Hosp
Iowa City, Iowa, 522421061
United States
Univ of CA - San Diego
San Diego, California, 921038770
United States
Elkhardt Gen Hosp
Elkhardt, Indiana, 46514
United States
Alta Bates Hosp
Berkeley, California, 94704
United States
Gulf Coast Clinical Services
Mobile, Alabama, 36603
United States
Louisiana State Univ
Shreveport, Louisiana, 711303932
United States
Texas Tech Univ Health Science Ctr
Lubbock, Texas, 79430
United States
Thomas Jefferson Univ Hosp
Philadelphia, Pennsylvania, 19107
United States
New Orleans Pharmaceutical Research
Kenner, Louisiana, 70062
United States
Brigham and Women's Hosp
Boston, Massachusetts, 02115
United States
Univ of Kansas Med Ctr
Kansas City, Kansas, 661607415
United States
Long Island Pain Management
Port Jefferson, New York, 11776
United States
Ctr for Pain Management and Rehabilitation
Huntsville, Alabama, 35801
United States
Cooper Hospital Early Intervention Program
Camden, New Jersey, 08103
United States
Univ of Missouri Med Ctr
Columbia, Missouri, 65212
United States
Clinical Solutions
Princeton, New Jersey, 08540
United States
H Lee Moffit Cancer Ctr and Research Institute
Tampa, Florida, 33612
United States
The Pain Institute
Kansas City, Missouri, 64132
United States
Univ of Miami School of Medicine
Miami, Florida, 33136
United States
Cook County Hosp
Chicago, Illinois, 60612
United States
Pain Control Ctr
Chicago, Illinois, 60612
United States
Univ of Texas Health Sciences Ctr
San Antonio, Texas, 782847838
United States
Emory Univ Hosp
Atlanta, Georgia, 30322
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21205
United States
Swedish Pain Management
Seattle, Washington, 98104
United States
Univ of Rochester
Rochester, New York, 14642
United States
Marschfield Clinic
Marshfield, Wisconsin, 544495777
United States
Pennsylvania State College of Medicine
Hershey, Pennsylvania, 17033
United States
Fairfax Hosp
Falls Church, Virginia, 220423300
United States
Additional Information:
Study ID Numbers: 256A;
Study Start Date:
Record last reviewed: March 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002160
Other Hiv Infections Studies:
1. A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients
2. The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
3. Male Circumcision and HIV Rates in Kenya
4. The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
5. A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
Related Studies:
Other HIV Infections Clinical Trials
Other Alabama Clinical Trials
Other Mobile Clinical Trials
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
|
|
|
|
|
|
|
|